HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock Fundamental Analysis

NASDAQ:HRMY • US4131971040

28.54 USD
-0.51 (-1.76%)
At close: Feb 27, 2026
28.54 USD
0 (0%)
After Hours: 2/27/2026, 8:08:54 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

Taking everything into account, HRMY scores 7 out of 10 in our fundamental rating. HRMY was compared to 193 industry peers in the Pharmaceuticals industry. HRMY scores excellent points on both the profitability and health parts. This is a solid base for a good stock. An interesting combination arises when we look at growth and value: HRMY is growing strongly while it also seems undervalued. These ratings would make HRMY suitable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year HRMY was profitable.
  • HRMY had a positive operating cash flow in the past year.
  • Each year in the past 5 years HRMY has been profitable.
  • In the past 5 years HRMY always reported a positive cash flow from operatings.
HRMY Yearly Net Income VS EBIT VS OCF VS FCFHRMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

1.2 Ratios

  • The Return On Assets of HRMY (12.48%) is better than 93.26% of its industry peers.
  • HRMY has a better Return On Equity (18.24%) than 90.16% of its industry peers.
  • HRMY's Return On Invested Capital of 15.30% is amongst the best of the industry. HRMY outperforms 94.82% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for HRMY is significantly above the industry average of 12.93%.
Industry RankSector Rank
ROA 12.48%
ROE 18.24%
ROIC 15.3%
ROA(3y)14.31%
ROA(5y)15.57%
ROE(3y)22.63%
ROE(5y)26.3%
ROIC(3y)18.27%
ROIC(5y)17.43%
HRMY Yearly ROA, ROE, ROICHRMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K 1.5K

1.3 Margins

  • The Profit Margin of HRMY (18.27%) is better than 90.67% of its industry peers.
  • In the last couple of years the Profit Margin of HRMY has declined.
  • Looking at the Operating Margin, with a value of 24.00%, HRMY belongs to the top of the industry, outperforming 91.19% of the companies in the same industry.
  • In the last couple of years the Operating Margin of HRMY has grown nicely.
  • The Gross Margin of HRMY (77.16%) is better than 83.94% of its industry peers.
  • In the last couple of years the Gross Margin of HRMY has remained more or less at the same level.
Industry RankSector Rank
OM 24%
PM (TTM) 18.27%
GM 77.16%
OM growth 3Y-4.37%
OM growth 5Y17.8%
PM growth 3Y-23.89%
PM growth 5YN/A
GM growth 3Y-1.58%
GM growth 5Y-1.37%
HRMY Yearly Profit, Operating, Gross MarginsHRMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • HRMY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for HRMY has been increased compared to 1 year ago.
  • The number of shares outstanding for HRMY has been increased compared to 5 years ago.
  • HRMY has a better debt/assets ratio than last year.
HRMY Yearly Shares OutstandingHRMY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
HRMY Yearly Total Debt VS Total AssetsHRMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • HRMY has an Altman-Z score of 4.48. This indicates that HRMY is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 4.48, HRMY is doing good in the industry, outperforming 73.06% of the companies in the same industry.
  • The Debt to FCF ratio of HRMY is 0.50, which is an excellent value as it means it would take HRMY, only 0.50 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 0.50, HRMY belongs to the best of the industry, outperforming 96.89% of the companies in the same industry.
  • A Debt/Equity ratio of 0.17 indicates that HRMY is not too dependend on debt financing.
  • HRMY has a Debt to Equity ratio of 0.17. This is comparable to the rest of the industry: HRMY outperforms 46.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF 0.5
Altman-Z 4.48
ROIC/WACC1.64
WACC9.34%
HRMY Yearly LT Debt VS Equity VS FCFHRMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M

2.3 Liquidity

  • HRMY has a Current Ratio of 3.60. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
  • HRMY has a Current ratio (3.60) which is comparable to the rest of the industry.
  • HRMY has a Quick Ratio of 3.58. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of HRMY (3.58) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.6
Quick Ratio 3.58
HRMY Yearly Current Assets VS Current LiabilitesHRMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.97% over the past year.
  • HRMY shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -4.69% yearly.
  • HRMY shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.51%.
  • Measured over the past years, HRMY shows a very strong growth in Revenue. The Revenue has been growing by 40.31% on average per year.
EPS 1Y (TTM)7.97%
EPS 3Y-4.69%
EPS 5YN/A
EPS Q2Q%-55.29%
Revenue 1Y (TTM)21.51%
Revenue growth 3Y25.64%
Revenue growth 5Y40.31%
Sales Q2Q%21.12%

3.2 Future

  • HRMY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.60% yearly.
  • HRMY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.49% yearly.
EPS Next Y59.48%
EPS Next 2Y40.12%
EPS Next 3Y54.88%
EPS Next 5Y35.6%
Revenue Next Year16.97%
Revenue Next 2Y14.81%
Revenue Next 3Y14.6%
Revenue Next 5Y9.49%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
HRMY Yearly Revenue VS EstimatesHRMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B
HRMY Yearly EPS VS EstimatesHRMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

10

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 10.53 indicates a reasonable valuation of HRMY.
  • Based on the Price/Earnings ratio, HRMY is valued cheaply inside the industry as 90.16% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 27.07, HRMY is valued rather cheaply.
  • A Price/Forward Earnings ratio of 6.60 indicates a rather cheap valuation of HRMY.
  • Based on the Price/Forward Earnings ratio, HRMY is valued cheaper than 93.26% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.05, HRMY is valued rather cheaply.
Industry RankSector Rank
PE 10.53
Fwd PE 6.6
HRMY Price Earnings VS Forward Price EarningsHRMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 97.93% of the companies in the same industry are more expensive than HRMY, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 96.37% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 5
EV/EBITDA 4.32
HRMY Per share dataHRMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of HRMY may justify a higher PE ratio.
  • A more expensive valuation may be justified as HRMY's earnings are expected to grow with 54.88% in the coming years.
PEG (NY)0.18
PEG (5Y)N/A
EPS Next 2Y40.12%
EPS Next 3Y54.88%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for HRMY!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HARMONY BIOSCIENCES HOLDINGS

NASDAQ:HRMY (2/27/2026, 8:08:54 PM)

After market: 28.54 0 (0%)

28.54

-0.51 (-1.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners85.16%
Inst Owner Change4.86%
Ins Owners1.63%
Ins Owner Change-0.04%
Market Cap1.64B
Revenue(TTM)868.45M
Net Income(TTM)158.69M
Analysts78.82
Price Target46.55 (63.1%)
Short Float %11.62%
Short Ratio8.91
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.41%
Min EPS beat(2)-58.44%
Max EPS beat(2)1.62%
EPS beat(4)2
Avg EPS beat(4)-9.25%
Min EPS beat(4)-58.44%
Max EPS beat(4)31%
EPS beat(8)6
Avg EPS beat(8)51.32%
EPS beat(12)8
Avg EPS beat(12)36.66%
EPS beat(16)11
Avg EPS beat(16)92.62%
Revenue beat(2)1
Avg Revenue beat(2)2.19%
Min Revenue beat(2)-0.58%
Max Revenue beat(2)4.96%
Revenue beat(4)1
Avg Revenue beat(4)-0.02%
Min Revenue beat(4)-3.46%
Max Revenue beat(4)4.96%
Revenue beat(8)1
Avg Revenue beat(8)-0.78%
Revenue beat(12)3
Avg Revenue beat(12)-0.81%
Revenue beat(16)5
Avg Revenue beat(16)-0.7%
PT rev (1m)-0.99%
PT rev (3m)0.2%
EPS NQ rev (1m)2.87%
EPS NQ rev (3m)2.68%
EPS NY rev (1m)2.3%
EPS NY rev (3m)4.73%
Revenue NQ rev (1m)1.75%
Revenue NQ rev (3m)1.75%
Revenue NY rev (1m)0.68%
Revenue NY rev (3m)3.2%
Valuation
Industry RankSector Rank
PE 10.53
Fwd PE 6.6
P/S 1.89
P/FCF 5
P/OCF 4.72
P/B 1.89
P/tB 2.11
EV/EBITDA 4.32
EPS(TTM)2.71
EY9.5%
EPS(NY)4.32
Fwd EY15.14%
FCF(TTM)5.71
FCFY19.99%
OCF(TTM)6.05
OCFY21.18%
SpS15.08
BVpS15.11
TBVpS13.56
PEG (NY)0.18
PEG (5Y)N/A
Graham Number30.35
Profitability
Industry RankSector Rank
ROA 12.48%
ROE 18.24%
ROCE 20.45%
ROIC 15.3%
ROICexc 63.88%
ROICexgc 100.8%
OM 24%
PM (TTM) 18.27%
GM 77.16%
FCFM 37.84%
ROA(3y)14.31%
ROA(5y)15.57%
ROE(3y)22.63%
ROE(5y)26.3%
ROIC(3y)18.27%
ROIC(5y)17.43%
ROICexc(3y)50.91%
ROICexc(5y)46.17%
ROICexgc(3y)83.62%
ROICexgc(5y)1001.65%
ROCE(3y)24.42%
ROCE(5y)23.3%
ROICexgc growth 3Y7.52%
ROICexgc growth 5YN/A
ROICexc growth 3Y24.53%
ROICexc growth 5Y26.45%
OM growth 3Y-4.37%
OM growth 5Y17.8%
PM growth 3Y-23.89%
PM growth 5YN/A
GM growth 3Y-1.58%
GM growth 5Y-1.37%
F-Score5
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF 0.5
Debt/EBITDA 0.61
Cap/Depr 77.21%
Cap/Sales 2.25%
Interest Coverage 14.2
Cash Conversion 148.93%
Profit Quality 207.1%
Current Ratio 3.6
Quick Ratio 3.58
Altman-Z 4.48
F-Score5
WACC9.34%
ROIC/WACC1.64
Cap/Depr(3y)27.76%
Cap/Depr(5y)157.72%
Cap/Sales(3y)0.82%
Cap/Sales(5y)8.9%
Profit Quality(3y)175.8%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.97%
EPS 3Y-4.69%
EPS 5YN/A
EPS Q2Q%-55.29%
EPS Next Y59.48%
EPS Next 2Y40.12%
EPS Next 3Y54.88%
EPS Next 5Y35.6%
Revenue 1Y (TTM)21.51%
Revenue growth 3Y25.64%
Revenue growth 5Y40.31%
Sales Q2Q%21.12%
Revenue Next Year16.97%
Revenue Next 2Y14.81%
Revenue Next 3Y14.6%
Revenue Next 5Y9.49%
EBIT growth 1Y0.5%
EBIT growth 3Y20.15%
EBIT growth 5Y65.28%
EBIT Next Year51.03%
EBIT Next 3Y28.56%
EBIT Next 5Y20.38%
FCF growth 1Y50.29%
FCF growth 3Y46.6%
FCF growth 5YN/A
OCF growth 1Y58.4%
OCF growth 3Y34.07%
OCF growth 5YN/A

HARMONY BIOSCIENCES HOLDINGS / HRMY FAQ

Can you provide the ChartMill fundamental rating for HARMONY BIOSCIENCES HOLDINGS?

ChartMill assigns a fundamental rating of 7 / 10 to HRMY.


What is the valuation status of HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?

ChartMill assigns a valuation rating of 10 / 10 to HARMONY BIOSCIENCES HOLDINGS (HRMY). This can be considered as Undervalued.


Can you provide the profitability details for HARMONY BIOSCIENCES HOLDINGS?

HARMONY BIOSCIENCES HOLDINGS (HRMY) has a profitability rating of 8 / 10.


What are the PE and PB ratios of HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?

The Price/Earnings (PE) ratio for HARMONY BIOSCIENCES HOLDINGS (HRMY) is 10.53 and the Price/Book (PB) ratio is 1.89.


What is the earnings growth outlook for HARMONY BIOSCIENCES HOLDINGS?

The Earnings per Share (EPS) of HARMONY BIOSCIENCES HOLDINGS (HRMY) is expected to grow by 59.48% in the next year.